Notably, we next validated BMP7 and MAPK14 expression and SMAD1 activation in samples from patients with NSCLC and adrenocortical carcinoma that progressed in the lung after treatment with pembrolizumab and ipilimumab, respectively. Here, BMP7 is linked to non-small cell lung carcinoma.